Showing results (121-130 of 172) with videos related to

Sort By:
Pageof 18
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 10, 2020
JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusionsT Yoshino, G Pentheroudakis, S Mishima, et al.
ESMO Open|May 1, 2026
Impact of treatment discontinuation among patients with microsatellite instability or mismatch repair-deficient metastatic colorectal cancer treated with immune checkpoint inhibitorsJ Ros, M C de Grandis, V Navarro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 12, 2015
Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trialF Sclafani, I Chau, D Cunningham, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 21, 2013
A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancerA L Cohn, J Tabernero, J Maurel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 12, 2017
Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III studyJ Tabernero, R R Hozak, T Yoshino, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 24, 2016
CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancerE G Chiorean, D D Von Hoff, M Reni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 23, 2014
Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II studyE Van Cutsem, C Boni, J Tabernero, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 1, 2026
A randomised study of encorafenib, cetuximab, and FOLFIRI versus FOLFIRI with or without bevacizumab in BRAF V600E-mutant colorectal cancer: BREAKWATER Cohort 3S Kopetz, J Tabernero, S Lonardi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 27, 2017
Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumabD Arnold, C S Fuchs, J Tabernero, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 9, 2014
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial datasetH Blons, J F Emile, K Le Malicot, et al.
Pageof 18